No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RCUS240517P17500
- 2.44
- +0.69+39.43%
15min DelayClose May 8 15:59 ET
2.44High2.44Low
2.44Open1.75Pre Close3 Volume21 Open Interest17.50Strike Price732.00Turnover102.33%IV-1.70%PremiumMay 17, 2024Expiry Date2.24Intrinsic Value100Multiplier8DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type-0.7829Delta0.1227Gamma6.10Leverage Ratio-0.0391Theta-0.0029Rho-4.78Eff Leverage0.0069Vega
Intraday
- 5D
- 1D
News
Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.0
Express News | Arcus Biosciences Inc -Well-Positioned to Advance Full Pipeline With $1.1 Bln in Cash, Cash Equivalents and Marketable Securities and Runway Into 2027
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.
1
Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.
Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.
Despite the weaker earnings outlook, the consensus price target suggests analysts do not anticipate a long-term impact on the company’s valuation. However, the downgrade of next year's forecast instills caution regarding Arcus Biosciences' future performance.
Read more